Gonorrhoea treatment could combat resistant infections
Newly published Phase III trial results suggest the new antibiotic gepotidacin could treat uncomplicated urogenital gonorrhoea (GC).
The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment regimen for gonorrhoea.
The results were published in the Lancet journal and presented at the annual European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna, Austria.
Gonorrhoea is caused by bacteria called Neisseria gonorrhoeae, which has been recognised by the World Health Organisation as a priority pathogen.
There is growing concern about the rise in antibiotic-resistant gonorrhoea cases, including ceftriaxone-resistant gonorrhoea.
Since first being detected in England in 2015, 42 cases of ceftriaxone-resistant gonorrhoea have been reported, according to the UK Health Security Agency (UKHSA). Fifteen of these cases were extensively drug-resistant (XDR), which means that they were resistant to ceftriaxone and to second line treatment options.
In the 15 months from January 2024 to 20 March 2025, there were 17 cases of ceftriaxone resistant gonorrhoea reported, compared to 16 across the previous two years.
XDR cases are also rising. From January 2024 to March 2025 there were 9 XDR cases, compared to five cases in total in the previous two years.
Commenting on the trial, Chris Corsico, SVP Development, GSK, said: “These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide including drug resistant infections. The imperative for innovative treatments has never been clearer. We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs.”
In March 2025, the US Food and Drug Administration (FDA) approved gepotidacin (Blujepa) for uncomplicated urinary tract infections (uUTIs).
Diana Spencer, Senior Digital Content Editor, DDW
